Rockley Photonics and Medtronic Collaboration for Non-invasive Wearables; Gan & Lee Dose First Patient with GZR18 in Ph1 T2DM Study; Xeris Biopharma and Zealand Q4 and FY ‘21 Earnings Updates
A series of cardiometabolic-related news items have been observed: Rockley Photonics Holdings Limited announced a development partnership with Medtronic to integrate Rockley’s Bioptx biomarker sensing platform with Medtronic’s devices across various healthcare settings; Gan and Lee announced the first patient has been dosed in their Ph1 study evaluating the company’s investigational GLP-1RA (GZR18) in T2DM; and Zealand (press release; slides) and Xeris (press release) hosted their respective earnings calls. Below, FENIX provides highlights and insights for the respective new items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.